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Abstract
Background: The delineation of pancreatic tumors on CT is challenging. In this study, we quantified the interobserver
variation for pancreatic tumor delineation on 3DCT as well as on 4DCT.
Methods: Eight observers (radiation oncologists) from six institutions delineated pancreatic tumors of four patients
with (borderline) resectable pancreatic cancer. The study consisted of two stages. In the 3DCT-stage, the gross tumor
volume (GTV) was delineated on a contrast-enhanced scan. In the 4DCT-stage, the internal GTV (iGTV) was delineated,
accounting for the respiratory motion. We calculated the volumes of the (i)GTV, the overlap of the delineated volumes
(expressed as generalized conformity index: CIgen), the local observer variation (local standard deviation: SD) and the
overall observer variation (overall SD). We compared these results between GTVs and iGTVs. Additionally, observers
were asked to fill out a questionnaire concerning the difficulty of the delineation and their experience in delineating
pancreatic tumors.
Results: The ratios of the largest to the smallest delineated GTV and iGTV within the same patient were 6.8 and 16.5,
respectively. As the iGTV incorporates the GTV during all respiratory phases, the mean volumes of the iGTV (40.07 cm3)
were larger than those of the GTV (29.91 cm3). For all patients, CIgen was larger for the iGTV than for the GTV. The mean
overall observer variation (root-mean-square of all local SDs over four patients) was 0.63 cm and 0.80 cm for GTV and
iGTV, respectively. The largest local observer variations were seen close to biliary stents and suspicious pathological
enlarged lymph nodes, as some observers included them and some did not. This variation was more pronounced for
the iGTV than for the GTV. The observers rated the 3DCT-stage and 4DCT-stage equally difficult and treated on average
three to four pancreatic cancer patients per year.
Conclusions: A considerable interobserver variation in delineation of pancreatic tumors was observed. This variation
was larger for 4D than for 3D delineation. The largest local observer variation was found around biliary stents and
suspicious pathological enlarged lymph nodes.
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Background
The aim of radiotherapy is delivering a high radiation
dose to the tumor while minimizing the dose to organs
at risk (OARs). For pancreatic tumors, this is challenging
due to day-to-day position variation, respiratory motion,
and uncertainties in delineation of the tumor [1–4].
The radiation oncologist can delineate the gross tumor
volume (GTV) on a three-dimensional CT (3DCT). The
GTV is expanded with a margin to account for microscopic
extensions, resulting in the clinical target volume (CTV).
For the remaining uncertainties, such as organ motion and
set-up uncertainties, an additional margin is added to form
the planning target volume (PTV). Nowadays, a four-
dimensional CT (4DCT) scan is increasingly used to
account for tumor motion during respiration [1, 2], for
example combined with the internal target volume (ITV)
[5] or mid-ventilation approach [6]. For pancreatic cancer
patients treated at our department, we combine 4DCT with
a modified ITV approach. In this approach, the radiation
oncologist delineates the GTV on the average scan of the
4DCT and expands that on all respiratory phases of the
4DCT to generate an internal GTV (iGTV). A 5 mm mar-
gin is then added to define the internal CTV (iCTV). An
additional PTV margin is added, to account for remaining
set-up uncertainties. This PTV margin can be smaller com-
pared with 3DCT delineation since respiratory motion un-
certainty is accounted for in this 4D approach. In both the
3DCT and 4DCT approaches it is important that appro-
priate margin size is used as too small a margin leads
to under-treatment of the target volume whereas too
large a margin leads to unnecessarily high doses to the
OARs. The CTV or iCTV to PTV margins currently
used to account for the delineation uncertainties in
pancreatic cancer are largely based on assumptions of
these uncertainties. To investigate whether these assump-
tions are correct we performed a delineation study.
Previous delineation studies quantified the interob-
server delineation uncertainties for several tumor sites
[7–11]. These studies resulted in standardized delinea-
tion protocols for those organs. For pancreatic cancer,
such a protocol is available in both postoperative setting
and preoperative setting [12, 13]. In the study of
Carvatta et al., standard criteria for CTV delineation of
high risk elective lymph node areas in preoperative or de-
finitive treatment with radiotherapy were developed [13].
Both guidelines were promoted and evaluated in a multi-
center dummy-run, and showed an acceptable interob-
server variation in delineation of these elective CTVs [14].
Only two other multi-institutional studies on the delinea-
tion of pancreatic tumors are available [15, 16]. All three
studies show large interobserver variation in GTV
delineation, with ratios of the largest to the smallest
GTV volume of 6.8 [14], 9 [15] and 3 [16]. Two of
these studies were quality control studies of a clinical
trial [15, 16]. Those studies only used 3DCT and in-
cluded 1–2 patients with locally advanced pancreatic
cancer [15, 16]. The third was a delineation study
which included two patients and only investigated
the interobserver variation using 3DCT [14]. All of
these studies reported limited quantitative information
(i.e., standard deviations, SD and generalized conformity
index, CIgen) [14–16].
The aim of this study was to quantify the interobserver
variation for GTV (3DCT) and iGTV (4DCT) delinea-
tions. The study included four patients with (borderline)
resectable pancreatic cancer, and eight radiation on-
cologists from six institutions.
Methods
Radiation oncologists (observers) from all nine institutions
participating in the PREOPANC trial were asked to
participate in this delineation study. Eight observers from
six institutions actually participated.
Patients’ characteristics
The data of four patients with histologically proven
(borderline) resectable pancreatic tumors were used
and anonymized. All patients gave written informed
consent for both the PREOPANC trial (EudraCT
number 2012-003181-40) and MIPA (NCT01989000)
study and were the first four patients that randomized for
preoperative radiochemotherapy at the Academic Medical
Center (AMC) within the PREOPANC trial [17]. Both
studies were approved by the local medical ethics
committee (PREOPANC: Erasmus Medical Center,
Rotterdam; MIPA: AMC, Amsterdam) [17]. Preopera-
tive radiochemotherapy consisted of 15 fractions of
2.4 Gy combined with gemcitabine 1000 mg/m2 once
a week for three weeks, preceded and followed by a
modified course of gemcitabine 1000 mg/m2, once a
week for two weeks. Between the three cycles there
was one week rest [17].
CT scans
Diagnostic CT scan
All patients had a contrast-enhanced diagnostic CT
scan in the referring hospital, which was considered
to be of adequate diagnostic quality by abdominal
radiologists from the AMC with extensive experience
in pancreatic cancer. The scans included an axial
scan in arterial contrast phase (on average 35 s after
injection, all patients), venous contrast phase (on
average 60 s after injection, patients 1,2 and 4) and/
or a portal contrast phase (on average 240 s after
injection, patients 1 and 4) with or without recon-
structed coronal views. Two experienced radiologists
from the AMC reported the studies. The radiology
report of patient 2 described two suspicious loco
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regional lymph nodes; the radiology report of patient
4 described some enlarged lymph nodes, which were
not further characterized.
Planning CT scan
The planning CT scans were obtained at the radiation
oncology department of the AMC with a GE LightSpeed
RT 16 scanner (General Electric Company, Waukesha,
WI) using a standard acquisition protocol (slice thickness
of 2.5 mm). Patients were scanned in treatment
position: supine on a flat table top with arms raised
above their heads.
First, a 3DCT scan was obtained during free breathing
after intravenous Iodine contrast injection. During the
same CT session, a few minutes after the 3DCT scan, a
4DCT scan was obtained. The patient’s breathing motion
was monitored and synchronized to the CT acquisition
by the respiratory gating system RPM (Real-Time Pos-
ition Management, Varian Oncology Systems, Palo Alto,
CA). For the 4DCT, images were captured during con-
tinuous respiration and divided into ten respiratory bins,
resulting in ten image sets of the respiratory cycle. Also,
a maximum intensity projection (MIP) and an average
intensity projection (Ave-IP) were reconstructed from
the ten phase scans. The planning CT scan was obtained
during the first modified course of gemcitabine (mean
eight days after the first administration of gemcitabine),
and on average six weeks (46–62 days, mean 53 days)
after the diagnostic CT. The 3DCT and 4DCT scans
were registered to each other but not to the diagnostic
CT scans.
Fiducial markers and biliary stents
All four patients had intratumoral fiducial markers,
which were placed under the guidance of endoscopic
ultrasound (EUS), for position verification during radio-
therapy [18, 19]. Patients 1, 3 and 4 had a pancreatic
head tumor and had received three intratumoral Visicoil
fiducial markers (RadioMed, Barlett, TN). For patient 2,
two Gold Anchor fiducial markers (Naslund Medical
AB, Huddinge, Sweden) and one Visicoil fiducial marker
had been placed, but mistakenly in the pancreas head
instead of in the corpus tumor. Also, all patients had
biliary drainage: patients 1–3 had fully covered metal
biliary stents, patient 4 had external percutaneous biliary
drainage. All markers, biliary stents and percutaneous
biliary drainage had been placed after the diagnostic
CT scans and were thus only visible on the planning
CT scan.
Delineation software
The Big Brother software, dedicated to radiotherapy
delineation studies was used, recording delineations as
well as observer-computer interactions [8]. Each observer
received a USB stick containing all CT scans, the radiology
report, the Big Brother software, and delineation instruc-
tions. These instructions were identical to those in the
PREOPANC trial protocol [17].
Delineation protocol
The study consisted of a 3DCT-stage and a 4DCT-stage.
In the 3DCT-stage, the observers were asked to de-
lineate the GTV on the 3DCT scan, which was dis-
played on the main window. The GTV was defined as
the macroscopically visible tumor and neighboring
suspicious pathological lymph nodes. A separate win-
dow was available for viewing the diagnostic CT scans.
A margin of 5 mm was automatically applied to create
the CTV.
In the 4DCT-stage, the Ave-IP reconstruction was dis-
played in the main window. The observers were asked to
delineate the GTV on the Ave-IP reconstruction and
then create an iGTV defined as the volume encompassing
the GTV on all ten respiratory phase image sets of
the 4DCT. The diagnostic CT scan, 3DCT scan, and
remaining 4DCT images including the MIP recon-
struction were available in a separate window. As the
3DCT and 4DCT scans from the planning CT were
obtained in the same session, the 3DCT and 4DCT
scans were linked to the Ave-IP reconstruction displayed
in the main window. Furthermore, a copy of the cursor
(linked cursor) was displayed at the corresponding loca-
tion in the secondary window when these scans were
displayed. Once finished with the iGTV delineations, a
margin of 5 mm was automatically applied to create the
iCTV. Completed delineations were sent back to the in-
vestigators by email.
Questionnaire
Observers were asked to fill out a questionnaire con-
taining eight questions about the delineation process
(Additional file 1). These multiple choice questions
about the delineation process included answers ranging
from very easy to very difficult in five steps. In addition,
there were three questions about the experience of the
observer in delineating pancreatic tumors as well as the
number of pancreatic cancer patients the observers
treated yearly within and outside the PREOPANC study
(Additional file 1).
Data analysis
The data were analyzed using the Big Brother software
[8]. The following analyses were repeated for the GTV,
iGTV, CTV and iCTV data.
Scatterplots were generated in GraphPad Prism (version
5.00, GraphPad Software, San Diego, CA) to present the
range of delineated volumes. Using the Big Brother soft-
ware we calculated the average volume of the (i)GTV and
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CIgen for each patient [20]. The CIgen is a measure of over-
lap of the delineated volumes and is defined as the ratio of
the sum over all observer pairs of the volumes common
to both observers and the sum over all observer pairs of
the encompassing volumes (volume delineated by at least
one of the two observers) [20]. CIgen ranges from 0–1,
where 1 indicates full overlap of the delineated volumes
from all observers and 0 indicates no overlap. To assess
the accuracy of CIgen we repeated its calculation a number
of times equal to the number of observers, leaving out one
different observer at each repetition. The range of results
from this leave-one-out procedure was reported. To test
for significant differences in average volumes, we used a
two-sided Wilcoxon signed-rank test (32 pairs, signifi-
cance level α = 0.05) using SPSS (version 22.0.0.2, IBM,
New York).
To determine the local observer delineation variation
per specific area of the (i)GTV/(i)CTV, we calculated for
each patient the median surface, i.e., the surface of the
volume that was included by at least 50% of the
observers [21]. The median surface was sampled with
approximately equidistant points at ~0.5 mm distance.
For each point on the median surface, the perpendicular
distance to each delineated (i)GTV/(i)CTV was measured.
When a delineated surface was not within 2 cm perpen-
dicular to a point on the median surface, the closest dis-
tance from that delineated surface to the reference point
on the median surface was used instead. For each point
on the median surface, the local observer variation was
calculated, defined as the SD of the obtained distances at
that point (local SD). Per patient, the overall observer
variation (overall SD) was calculated. The overall SD was
defined as the root-mean-square of the local SDs. Similar
as for the CIgen, the overall SD was repetitively calculated
in a leave-one-out procedure and the range was reported.
The answers to the questionnaire were plotted in a
scatterplot using GraphPad Prism and the ratings of the
difficulty of the delineation between both stages were
compared.
Results
Eight observers from six different institutions submitted
all GTV and iGTV delineations. The analyses of the
delineations reported in this results section were per-
formed on the (i)GTV. The results from the (i)CTV
are presented in Additional file 2.
Delineations
Visual inspection of the delineations revealed considerable
interobserver variations (Figs. 1 and 2). The ratio of the
largest to the smallest delineated GTV and iGTV was 6.8
and 16.5, respectively, both in patient 3. The iGTV
volumes were significantly larger than the GTV volumes
by 34% (P = 0.036). However, for two observers, the
delineated iGTV was smaller than the delineated GTV in
all four patients (observers 2 and 5; Fig. 3) and for patient
2 two additional observers (6 and 7) also delineated a
smaller iGTV than GTV. Observer 7 reported that his/her
iGTV was not based on the ten separate respiratory
phases of the 4DCT, due to poor image quality. As the
iGTV was delineated on the Ave-IP of the 4DCT, the
iGTV still contained 4DCT information. The CIgen was
larger for the GTV (mean CIgen =0.37) than for the iGTV
(mean CIgen =0.27) for all four patients, indicating a better
overlap of volumes in 3D delineation than in 4D delinea-
tion (Table 1).
Local observer variation
The local observer variation (local SD) reflects the vari-
ation locally projected on the (i)GTV.
There was a large local SD at the laterodorsal borders
of the GTV and iGTV of patients 1–3 (Figs. 1 and 4a–
b), reflecting the location of the biliary stent. Some
observers did, and some did not include the biliary stent
in the GTV/iGTV. The biliary stent was included most
Fig. 1 For the four patients, delineations of GTV projected onto an
axial 3DCT slice (left) and iGTV projected onto an axial 4DCT Ave-IP
slice (right) for all eight observers. Colors are related to observers
and are similar for Figs.2, 3 and 5
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often in patient 3: by six observers in the GTV and by
four observers in the iGTV (Additional file 3). Especially
in patient 2, large local variation was seen. The suspicious
pathologically enlarged lymph node in the portocaval
space was incorporated in the GTV by five (observers 1-5)
and in the iGTV by four (observers 1,3,4 and 8) observers.
The suspicious pathologically enlarged lymph node along
the common hepatic artery was included in the GTV by
three (observers 2–4) and in the iGTV by two (observers
3 and 4) observers (Additional file 3). Also for patient 2,
only observer 2 included all the misplaced fiducial
markers in the GTV and only observer 1 included all the
fiducial markers in the iGTV. For all patients, there was
some variation in including the fiducial markers in the
delineated volume (Additional file 3). Finally, the caudal
side of tumors had larger local SDs than the other areas of
the tumors (Fig. 4a–d).
Overall observer variation
The overall observer variation, represented by the overall
SDs of the (i)GTV, was smaller for the GTV delineations
(SD = 0.63 cm) compared with the iGTV delineations (SD
= 0.80 cm) for all four patients (Table 1). Due to the ob-
served discrepancy in including the suspicious pathologic-
ally enlarged lymph nodes in patient 2, we recalculated the
overall SD while excluding the portocaval lymph node; the
overall SD decreased from 0.84 to 0.72 cm for the GTV
and from 0.90 to 0.49 cm for the iGTV.
Questionnaire
Seven observers filled out the structured part of the ques-
tionnaire; eight observers the open questions. With a mean
score of 3.6 for the difficulty of the delineations in both the
3DCT-stage and 4DCT-stage (Fig. 5), the observers did not
consider the iGTV (4DCT) delineation more difficult than
the GTV (3DCT) delineation. Of the eight observers that
filled out the open questions, one radiation oncologist only
just started to treat patients with pancreatic cancer. The
remaining seven observers treat on average three to four
pancreatic cancer patients per year at their institution
(range 1–7.5) and on average they had 5.4 years of experi-
ence in delineating pancreatic tumors (range 2–12.5). On
average, the observers treated one patient (range 0–4) with
pancreatic cancer within the PREOPANC trial. Two ob-
servers mentioned in the remarks section that the long
interval between the diagnostic scan and planning CT scan
(average six weeks) made interpretation more challenging.
Fig. 2 For the four patients, the expansion of the CTV projected
onto an axial 3DCT slice (left) and iCTV projected onto an axial 4DCT
Ave-IP slice (right) for all eight observers. Colors are related to observers
and are similar for Figs.1, 3 and 5
Fig. 3 Scatterplots of GTV (left) and iGTV (right) of all four patients with the median and 25th and 75th percentile represented by the horizontal
lines. Colors are related to observers and are similar for Figs.1, 2 and 5
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Table 1 The average delineated target volumes, overall SDs and CIgen for all 4 patients
Patient GTV (rangea) iGTV (rangea)
1 Average volume (cm3) 36.71 (14.02–75.87) 41.80 (11.85–89.99)
Overall SD (cm) 0.70 (0.47–0.72) 0.71 (0.60–0.72)
CIgen 0.34 (0.31–0.37) 0.29 (0.26–0.31)
2 Average volume (cm3) 20.26 (7.06–45.21) 20.57 (4.67–67.86)
Overall SD (cm) 0.84 (0.70–0.88) 0.90 (0.37–0.90)
CIgen 0.22 (0.20–0.27) 0.20 (0.17–0.27)
3 Average volume (cm3) 10.36 (2.91–19.92) 32.38 (5.67–93.58)
Overall SD (cm) 0.48 (0.42–0.51) 0.89 (0.77–0.94)
CIgen 0.34 (0.30–0.37) 0.16 (0.12–0.19)
4 Average volume (cm3) 52.32 (34.18–76.72) 65.52 (21.48–119.09)
Overall SD (cm) 0.43 (0.38–0.44) 0.68 (0.58–0.70)
CIgen 0.59 (0.57–0.62) 0.45 (0.42–0.50)
Overall for all patients Average volume (cm3) 29.91 40.07c(P = 0.036)
Overall SD (cm)b 0.63 0.80
CIgen 0.37 0.27
Abbreviations: GTV gross tumor volume, iGTV internal gross tumor volume, SD standard deviation, CIgen generalized conformity index
aRange over eight delineations (average volume) or over results of the leave-one-out analysis (overall SD and CIgen)
bNote that this overall SD was calculated as the root-mean-square of the four overall SDs from the four patients
cTwo-sided Wilcoxon signed-rank test
Fig. 4 For the four patients, the local observer variation in color expressed in local SD (centimeters) of the delineations of GTV in posterior (a)
and caudal view (c) and the iGTV in posterior (b) and caudal view (d) projected onto the median surface. Red indicates a local SD≥ 0.94 cm
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Discussion
This multi-institutional delineation study is the first to
quantify the interobserver variation on both 3DCT and
4DCT. Also, contrary to earlier studies, this study is per-
formed with more than two patients with (borderline)
resectable pancreatic cancer. A considerable variation
among observers was observed in both GTV (3DCT)
and iGTV (4DCT) delineations. The ratio of the largest
to the smallest delineated volume was far larger for
iGTV than for GTV, with significantly larger average
volumes for the iGTV. Furthermore, the GTV delinea-
tions had larger CIgen and smaller overall SDs in all pa-
tients compared to the iGTV. The largest variation in
delineation was seen close to biliary stents and suspi-
cious pathologically enlarged lymph nodes. Previous
studies in pancreatic cancer also showed a large interob-
server variation on 3DCT with a comparable ratio of
largest to smallest GTV of 3–9 [14–16]. The observed
interobserver variation is large compared to studies
performed in several other organs such as breast,
larynx, and rectal cancer, which reported a CI of 0.6–
0.82 [9, 22, 23].
The average iGTV volumes were significantly larger
than the GTV volumes by 34%. This is similar compared
to previous studies in pancreatic cancer, where the iGTV
was 25–27.6% larger than the GTV [2, 24]. As the iGTV
should incorporate the GTV in all respiratory phases,
this result can be expected. However, unexpectedly, in
several cases in our study, observers delineated a smaller
iGTV than GTV. This may be a result of a large intraob-
server variation, which was not specifically assessed in
this study. Alternatively, it could be a result of a difference
in image quality between the 3DCT and 4DCT images. It
is known that inaccuracies in delineation of the tumor
may be due to poorly defined tumor edges on the
planning CT images [1, 2, 14–16].
The 4DCT delineations had a larger interobserver
variation than the 3D delineations, as reflected in the
larger overall SDs of the iGTV compared to the GTV in
all four patients and the smaller CIgen. This may be the re-
sult of poor visibility of the tumor on the various respira-
tory phases of the 4DCT. Poor visibility can lead to bigger
uncertainty and thus larger target volumes and variation
in the delineation. The larger interobserver variation on
4DCT counteract the advantage of the ITV concept:
accounting for the respiratory motion. Other delineation
approaches with improved contrast between tumor and
surrounding tissue to define the tumor borders and
including the respiration motion should be investigated
such as midventilation and particularly the midposition
approach. Previous research showed that a midventilation
approach results in significant PTV reduction and signifi-
cant dose reductions to OARs compared to the iGTV
approach, although the delineation process had not been
investigated yet [6].
The largest local variation was seen at the laterodorsal
side of the (i)GTV, corresponding to the location of the
biliary stent. Some observers included the stent in the
(i)GTV, whereas others excluded the stent. Also, some
observers included the stent only in the GTV but not in
the iGTV. In the literature, there is no guideline pre-
scribing to include or exclude the biliary stent in the
(i)GTV and none was given in the protocol instructions
of the PREOPANC trial. The caudal side of the (i)GTV
also showed large variations in delineations, similar to a
previous study of Caravatta et al. [14].
Also, large variations in the delineation of the suspicious
pathologically enlarged lymph nodes around the tumor
were seen. The protocol prescribes to include all neigh-
boring suspicious pathological lymph nodes. The reason
for the large local variation that was found around suspi-
cious pathologically enlarged lymph nodes could be due
to misinterpretation or ambiguity of protocol instructions,
or poor compliance with the protocol instructions. This
could also result in the wide range of the separate delinea-
tions, with ratios of the largest to the smallest GTV and
Fig. 5 Scatterplot of the delineation difficulty rating by seven observers (observer 2 missing), showing the range, the median, 25th, 75th percentile
for eight delineations. Rating varied between 1 = very easy; 2 = easy; 3 =moderate; 4 = difficult; 5 = very difficult. Colors are related to observers
and are similar for Figs.1, 2 and 3
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iGTV of 6.8 and 16.5. For the GTV these ratios are similar
compared to previous studies [14–16], for the iGTV there
is no data to compare. To increase interobserver agree-
ment, consensus on the delineation of pancreatic tumors,
pathologically enlarged lymph nodes, and biliary stents
should be achieved among radiation oncologists. The pro-
posed guidelines of the high risk nodal areas and CTV
delineation described by Carvatta et al. might be used to
reduce delineation variation in elective CTVs [13, 14]. The
lack of guidelines concerning the GTV margin could be
an important cause of increased variation of the boost
CTV compared to the elective CTV [14]. Also in the post-
operative setting, guidelines serve to develop appropriate
radiation fields in the setting of very difficult anatomy in
the postoperative setting and to ensure that areas at risk
are included in the field while organs at risk are spared
[12]. Previous research in other organs showed that
national consensus guidelines and a delineation atlas may
result in reduction of the interobserver delineation vari-
ation [10, 25]. Especially for a clinical trial, improve-
ment of interobserver agreement is important. The
study of Abrams et al. showed that failure to adhere to
specified radiation guidelines was associated with infer-
ior survival [26].
To optimize tumor visibility, the repetition of the diag-
nostic scan in treatment position after stenting and
placement of the fiducial markers may be a step forward.
For the patients in our study, registration between the
diagnostic CT and the planning CT was not performed
because of a different position of the patient and a differ-
ent anatomy as a result of the placement of the biliary
stents and fiducial markers between both scans. Image
registration between a diagnostic scan and planning CT
scan may improve accuracy in target delineation and
reduce interobserver variation as seen for other tumor
sites [27–29].
It is well known that pancreatic tumors are difficult to
distinguish from normal pancreas tissue on diagnostic
CT scans [2, 30, 31]. Therefore, exploitation of other
imaging modalities, such as MRI and PET-CT may be a
step forward to reduce the variation in delineation of
pancreatic tumors. Indeed, other studies have shown
that additional imaging, such as MRI and PET-CT,
may be helpful in the delineation of pancreatic tu-
mors [32, 33].
Limitations
Delineations were only performed once, and we could not
investigate the intraobserver variation. Furthermore, we
had a limited number of responding observers, and only a
limited number of patients were included. Also, the ob-
servers had little experience in the delineation of pancreatic
tumors, due to the small number of pancreatic cancer
patients eligible for radiotherapy. However, this is typical
for many radiation oncologists and hence the found
observer variations should be representative for such
radiation oncologists.
The time interval between diagnostic CT and planning
CT scan was on average six weeks and the patients were
not scanned in treatment position; therefore, anatomical
changes (including placement of the biliary stent) oc-
curred between both scans and scans were not regis-
tered. This made it challenging to delineate the (i)GTV.
However, this is a typical situation in clinical practice in
many hospitals since the diagnostic CT is obtained be-
fore histological diagnosis, while therapeutic measures
such as stenting are performed after the diagnostic CT
scan. The fiducial markers in patient 2 were mistakenly
not placed inside the tumor, which may have put some
observers on the wrong track and contributed to the
large interobserver variation seen in this patient.
Conclusion
This study showed a considerable interobserver variation
in delineation of pancreatic tumors, larger for 4DCT than
for 3DCT delineation. The local variation was largest
around the biliary stent and suspicious pathologically
enlarged lymph nodes. In the future, better guidelines and
the addition of other imaging modalities, such as PET or
MRI may help decrease observer variation.
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